Clinical Trial Update: Open-Label, Extension Study to 810P202 [Phase 2]

View source ↗

Summary

Open-label extension of a Phase 2 study (810P202) for impulsive aggression comorbid with ADHD in children; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• QELBREE (viloxazine hydrochloride)

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Impulsive Aggression Comorbid With ADHD in Children | Phase 2 | Status: COMPLETED